Purpose: To activate and propagate populations of gd T cells expressing polyclonal repertoire of g and d T-cell receptor (TCR) chains for adoptive immunotherapy of cancer, which has yet to be achieved.
Introduction
Human gd T cells exhibit an endogenous ability to specifically kill tumors and hold promise for adoptive immunotherapy. They have innate and adaptive qualities exhibiting a range of effector functions, including cytolysis upon cell contact (1, 2) . Recognition and subsequent killing of tumor is achieved upon ligation of antigens to heterodimers of g and d T-cell receptor (TCR) chains. The human TCR variable (V) region defines 14 unique Vg alleles (TRGV), 3 unique Vd alleles (TRDV1, TRDV2, and TRDV3), and 5 Vd alleles that share a common nomenclature with Va alleles (TRDV4/TRAV14, TRDV5/TRAV29, TRDV6/ TRAV23, TRDV7/TRAV36, and TRDV8/TRAV38-2; ref. 3) . T cells expressing TCRa/TCRb heterodimers compose approximately 95% of peripheral blood T cells and recognize peptides in the context of MHC (4) . In contrast, TCRgd ligands are recognized independent of MHC and these cells are infrequent (1%-5% of T cells) in peripheral blood (1, 5, 6) . Many conserved ligands for TCRgd are present on cancer cells, thus an approach to propagating these T cells from small starting numbers while maintaining a polyclonal repertoire of gd TCRs has appeal for human application.
Clinical trials highlight the therapeutic potential of gd T cells, but numeric expansion is needed for adoptive immunotherapy because they circulate at low frequencies in peripheral blood. Methods to propagate ab T cells, for e. g., using interleukin-2 (IL2) and/or antibody cross-linking CD3, cannot sustain proliferation of gd T cells (7, 8) . Aminobisphosphonates, for e.g., zoledronic acid, have been used to initiate a proliferative signal in gd T cells (5, 9) , but only one lineage of gd T cells, expressing Vg9Vd2 TCR, can be reliably expanded by zoledronic acid. The adoptive transfer of Vg9Vd2 T cells has yielded clinical responses for investigational treatment of solid and hematologic cancers (10) (11) (12) (13) (14) . Furthermore, long-term remission of leukemia among recipients of haploidentical ab T-cell-depleted hematopoietic stem cell transplantation (HSCT) correlated with increased frequency of engrafted donor-derived Vd1 cells (8, (15) (16) (17) . However, direct administration of Vd1 cells or other non-Vg9Vd2 cell lineages has yet to be performed. In addition, no reports to date have described the therapeutic impact of Vd1 neg Vd2 neg cells in cancer immunotherapy and this subset has not been directly compared with T cells expressing Vd1 and Vd2 TCRs. Thus, there are significant gaps in the knowledge and human application of nonVg9Vd2 lineages.
Given that gd T cells have endogenous anticancer activity, such as against K562 cells (8, 18) , we hypothesized that malignant cells would serve as a cellular substrate to propagate polyclonal gd T cells. K562 cells have been genetically modified to function as artificial antigenpresenting cells (aAPC) to ex vivo activate and numerically expand ab T cells and NK cells (19) (20) (21) (22) (23) . We determined that IL2, IL21, and g-irradiated K562-derived aAPCs (designated clone #4, genetically modified to coexpress CD19, CD64, CD86, CD137L, and a membrane-bound mutein of IL15 (mIL15); used in selected clinical trials at MD Anderson Cancer Center, Houston, TX) can sustain the proliferation of gd T cells with polyclonal TCR repertoire. Polyclonal gd T cells exhibited broad tumor reactivity and displayed a multivalent response to tumors as evidenced by the ability of separated Vd subpopulations to kill and secrete cytokine against the same tumor target. Furthermore, killing by polyclonal populations was multifactorial being mediated through DNAM1, NKG2D, and TCRgd. Tumor xenografts were eliminated by both polyclonal and distinct gd T-cell subsets, and mice treated with polyclonal gd T cells had superior survival. Given the availability of aAPCs as a clinical reagent, trials can, for the first time, evaluate polyclonal populations of gd T cells as a cancer immunotherapy.
Materials and Methods

Cell lines
HCT-116, Kasumi-3, and K562 were acquired from ATCC. Jurkat was purchased from Deutsche Sammlung von Mikroorganismen und Zellkulturen. cALL-2 and RCH-ACV were gifts from Dr. Jeff Tyner (Oregon Health & Science University, Portland, OR). BxPC-3, MiaPaCa-2, and Su8686 (pancreatic cancer) were donated by Dr. Vijaya Ramachandran (MD Anderson Cancer Center). A2780, CAOV3, EFO21, EFO27, Hey, IGROV1, OAW42, OC314, OVCAR3, and UPN251 (ovarian cancer) were provided by Dr. Robert C. Bast, Jr. (MD Anderson Cancer Center, Houston, TX). Identities of all cell lines were confirmed by STR DNA Fingerprinting at MD Anderson Cancer Center's "Characterized Cell Line Core" and cells were used within 6 months of authentication.
Propagation of gd T cells
Peripheral blood mononuclear cells (PBMC) and umbilical cord blood (UCB) were isolated from healthy volunteers by Ficoll-Hypaque (GE Healthcare) after informed consent (24) . Thawed PBMCs (10 8 ) were initially treated with CD56 microbeads (cat# 130-050-401, Miltenyi Biotec) and separated on LS columns (cat# 130-042-401, Miltenyi Biotec) to deplete NK cells from cultures because they proliferate on aAPCs (23) and would contaminate the purity of the gd T-cell product. Unlabeled cells from CD56 depletion sorting were then labeled with TCRg/dþ T-cell isolation kit (cat# 130-092-892, Miltenyi Biotec) and placed on LS columns to separate gd T cells in the unlabeled fraction from other cells attached to magnet. gd T cells were cocultured at a ratio of one T cell to two g-irradiated (100 Gy) aAPCs (clone #4) in presence of exogenous IL2 (Aldesleukin; Novartis; 50 IU/mL), and IL21 (cat# AF20021; Peprotech; 30 ng/mL) in complete media (CM; RPMI, 10% FBS, 1% Glutamax). Cells were serially restimulated with addition of g-irradiated aAPCs every 7 days for 2 to 5 weeks in presence of soluble cytokines, which were added three times per week beginning the day of aAPC addition. K562 were genetically modified to function as aAPCs (clone #4) as previously described (25, 26) . Validation of coexpression of CD19, CD64, CD86, CD137L, and eGFP (IL15 peptide fused in frame to IgG4 Fc stalk and coexpressed with eGFP) on aAPC clone #4 was performed before addition to T-cell cultures (25 (TCRd1   neg   TCRd2 neg ) populations, which were stimulated twice as above with aAPC clone #4, phenotyped, and used for functional assays. gd T cells from UCB were isolated by FACS from thawed mononuclear cells using anti-TCRgd and anti-CD3 monoclonal antibodies (mAb) and were stimulated for 5 weeks on aAPCs/cytokines as per PBMCs.
Abundance and identity of mRNA molecules by DTEA At designated times after coculture on aAPCs, T cells were lysed at a ratio of 160 mL RLT buffer (Qiagen) per 10 6 cells and frozen at À80 C. RNA lysates were thawed and
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immediately analyzed using nCounter Analysis System (NanoString Technologies) with "designer TCR expression array" (DTEA), as previously described (27, 28) . DTEA data were normalized to both spiked positive control RNA and housekeeping genes (ACTB, G6PD, OAZ1, POLR1B, POLR2A, RPL27, RPS13, and TBP). Spiked positive control normalization factor was calculated from the average of sums for all samples divided by the sum of counts for an individual sample. Spiked positive control normalization factor was calculated from the average of geometric means for all samples divided by the geometric mean for an individual sample. Normalized counts were reported.
Flow cytometry
Cells were phenotyped with antibodies detailed in Supplementary Table S1 . Gating strategy is displayed in Supplementary Fig. S1 . Samples were acquired on FACS Calibur (BD Biosciences) and analyzed with FlowJo software (version 7.6.3).
Cytokine production and cytolysis assays
Expression of cytokines was assessed by intracellular staining and secretion of cytokines into tissue culture supernatants was evaluated by Luminex multiplex analysis. In vitro specific lysis was assessed using a standard 4-hour CRA, as previously described (25) . Additional information can be found in the Supplementary Materials and Methods.
Mouse experiments
In vivo antitumor efficacy was assessed in NSG mice (NOD.Cg-Prkdc scid Il2rg tm1Wjl /SzJ; Jackson Laboratories). CAOV3 ovarian cancer cell line was transduced with recombinant lentivirus ( Supplementary Fig. S2 ) encoding mKate red fluorescence protein (29) to identify transduced cells and enhanced firefly luciferase (effLuc) for noninvasive bioluminescence imaging (30) . CAOV3-effLuc-mKate (clone 1C2; 3 Â 10 6 cells/mouse) tumors were established by intraperitoneal injection and mice were randomly distributed into treatment groups. Eight days later (designated day 0), a dose escalation regimen was initiated with gd T cells and PBS (negative control) administered intraperitoneally. T-cell doses were 3 Â 10 6 , 6 Â 10 6 , 10 7 , and 1.5 Â 10 7 on days 0, 7, 14, and 21, respectively. Noninvasive bioluminescence images (BLI) was performed during the course of the experiments to serially measure tumor burden of CAOV3-effLuc-mKate following subcutaneous administration of D-Luciferin (cat#122796, Caliper) as detected with IVIS-100 Imager (Caliper). BLI was analyzed using Living Image software (version 2.50, Xenogen, Caliper).
Results
Ex vivo numeric expansion of gd T cells on aAPCs depends on costimulation and cytokines
The adoptive transfer of gd T cells requires ex vivo propagation as starting numbers from PBMCs are limiting (gating on lymphocyte pool: 3.2% AE 1.2%; mean AE SD; n ¼ 4; Fig. 1A ). gd T cells from PBMCs were isolated by "negative" paramagnetic bead selection and cocultured for 22 (Fig. 1A far right) . Cells were activated as marked by expression of CD38 (93.5% AE 3.5%) and CD95 (99.7% AE 0.1%; Supplementary Fig. S3 ). This approach to propagation yielded >10 9 gd T cells from <10 6 total initiating cells (Fig. 1B) , which represented a 4.9 Â 10 3 AE 1.7 Â 10 3 (mean AE SD; n ¼ 4) fold increase. Thus, aAPCs with recombinant human cytokines supported the robust numeric expansion of polyclonal gd T cells from small starting numbers of gd T cells derived from PBMCs.
The addition of exogenous cytokines and presence of mIL15, CD86, and CD137L on clinical-grade aAPCs were assessed for their ability to support the outgrowth of gd T cells. Parental K562 cells were stably transfected with Sleeping Beauty (SB) transposons to introduce individual stimulatory molecules, cloned to achieve homogeneous expression ( Supplementary Fig. S4 ), and then used to assess their impact on gd T-cell proliferation. Cocultures with exogenous IL2 and IL21 were initiated with paramagnetic bead-purified gd T cells and five sets of g-irradiated K562:
in parallel without APC demonstrated that soluble IL2 and IL21 sustained only limited numeric expansion of gd T cells (Fig. 1C) . Propagation improved upon addition of parental K562 cells, indicating that endogenous molecules on these cells can activate gd T cells for proliferation. The expression of mIL15 with or without CD86 did not further improve the ability of gd T cells to propagate compared with parental K562. In contrast, improved rates of propagation of gd T cells were observed upon coculture with mIL15
Thus, it appears that CD137L on aAPC clone#4 provides a dominant costimulatory proliferative signal for gd T cells. In the absence of IL2 and IL21, the proliferation of gd T cells ceased on aAPC clone#4, and together these cytokines exhibited an additive benefit to the rate of gd T-cell propagation (Fig. 1D ). This validated our approach to combining aAPC clone #4 with cytokines to sustain the proliferation of polyclonal gd T cells ex vivo, and demonstrated that CD137L on aAPCs, IL2, and IL21 were driving factors for proliferation of polyclonal gd T cells to clinical scale.
Ex vivo numeric expansion of neonatal gd T cells on aAPCs in presence of IL2 and IL21
Allogeneic UCB is an important source of gd T cells for adoptive transfer, because it contains younger cells and a more diverse TCRgd repertoire relative to PBMCs, which could increase the number of ligands targeted by the engrafted cells and result in long-term engraftment in the recipient (31) . However, the limited number of mononuclear cells within a banked UCB unit curtails the number of neonatal gd T cells directly available for adoptive transfer. Thus, we evaluated whether aAPCs could sustain proliferation from small starting numbers of neonatal gd T cells. Fluorescence-activated cell sorting (FACS) was used to isolate 10 4 UCB-derived gd T cells ($0.01% of a typical UCB unit) which were cocultured on aAPC clone #4 with IL2 and IL21. After 35 days, there was a 10 
S5B-S5D).
Collectively, these data demonstrate that aAPC clone #4 with IL2 and IL21 could sustain the ex vivo proliferation of gd T cells from a small starting population of neonatal UCB.
Ex vivo activated and propagated gd T cells express polyclonal and defined TCRgd repertoire Upon establishing that gd T cells could numerically expand on aAPCs and selected cytokines, we sought to determine the TCR repertoire of the propagated cells. Before numeric expansion, resting gd T-cell repertoire followed TCRd2>TCRd1 neg TCRd2 neg >TCRd1 by flow cytometry (Supplementary Fig. S6 ). However, the gd T-cell repertoire followed TCRd1>TCRd1 neg TCRd2 neg >TCRd2 following expansion, suggesting that there was a proliferative advantage for Vd1 cells within polyclonal gd T-cell cultures. To look more in-depth at TCRgd diversity in aAPC-expanded gd T cells, we adapted a nonenzymatic digital multiplex assay used to quantify the TCR diversity in gd T cells expressing a CD19-specific chimeric antigen receptor (CAR; ref. 27) termed DTEA. After expansion (day 22), 4 of 8 Vd alleles (TRDV1, TRDV2-2, TRDV3, and TRDV8) were detected in PBMC-derived gd T cells ( Fig. 2A ) and were coexpressed with Vg alleles TRGV2, TRGV7, TRGV8 (two probes), TRGV9 Ã A1, TRGV10 Ã A1, and TRGV11 Ã 02 (Fig.  2B) . Similarly, a polyclonal assembly of Vd and Vg chains was observed in gd T cells from UCB following expansion (days [34] [35] , albeit with reduced abundance of TRDV2-2, more TRGV2, and presence of TRGV3F, TRDV5, and TRDV7 cells not seen from PBMCs ( Fig. 2C and D) . Similar patterns of Vd and Vg mRNA usage were detected in PBMCs and UCB before and after expansion ( Supplementary Fig. S7 ) although overall mRNA counts were fewer in the resting cells (day 0) relative to the activated gd T cells. Thus, aAPCexpanded gd T cells maintain a polyclonal TCR repertoire from both PBMCs and UCB.
We sought to validate these mRNA data by sorting polyclonal populations with TCRd-specific antibodies and (Fig. 1A) and UCB ( Supplementary Fig. S8 ) with abundance following Vd1>Vd1 neg Vd2 neg >Vd2. FACS-isolated subsets from PBMC-derived gd T-cell pools were propagated with clone #4 as discrete populations and maintained their identity as assessed by expression of TCRd isotypes (Fig. 3A) . Each of the separated subsets could be identified by a pan-specific TCRgd antibody confirming that these cells were indeed gd T cells (Fig. 3B) (Fig. 3C) indicating that the observed inversion of Vd1 and Vd2 frequencies in polyclonal cultures before versus after expansion was not due to a proliferative defect in one of the subsets. DTEA demonstrated that isolated and propagated Vd1, Vd2, and Vd1 neg Vd2 neg subpopulations were homogeneous populations as they predominantly expressed TRDV1, TRDV2-2, and TRDV3 mRNA species at 261 AE 35, 3,910 AE 611, and 5,559 AE 1119 absolute counts, respectively (Fig. 3D) . Therefore, there were fewer TRDV1 mRNA species expressed by Vd1 cells relative to the TRDV2-2 expressed by Vd2 cells and TRDV3 expressed by Vd1 neg Vd2 neg cells. Moreover, these data indicated that the relatively low counts observed for TRDV1 in polyclonal populations with a preponderance of TCRd1 þ cells was not a defect in DTEA detection but rather a product of fewer total mRNA transcripts relative to other Vd species. Given the wide range of mRNA . Solid lines at bottom of graphs represent limit-of-detection (LOD) calculated from mean AE 2 Â SD of DTEA-negative controls. Student paired one-tailed t tests were performed for each allele relative to the sample LOD. Ã , P < 0.05; ÃÃ , P < 0.01.
transcript quantities for each allele, DTEA was not useful for calculation of relative frequencies of Vd subsets in polyclonal populations but rather was indicative of presence or absence of a particular gd T-cell subset. Expression of other Vd2 alleles (TRDV2-1 and TRDV2-1F) was absent from polyclonal gd T cells ( Fig. 2A) and each of the sorted subsets (data not shown). Small amounts of TRDV4, TRDV5, TRDV6, and TRDV7 mRNA species were detected in the three subsets of T cells sorted for Vd expression ( Supplementary Fig. S9 ). TRDV8 mRNA was exclusively present in sorted Vd1 neg Vd2 neg cells and these T cells are likely the main contributors of TRDV8 in bulk gd T cells. The same Vg mRNA present in polyclonal cultures was detected in Vdsorted cultures (Supplementary Fig. S10 ). Furthermore, Vd1 and Vd1 neg Vd2 neg were not different (P ¼ 0.419; two-way ANOVA) but Vd2 was different to both Vd1 (P < 0.0001) and Vd1 neg Vd2 neg (P < 0.0001) in Vg usage. Collectively, these results confirmed DTEA from unsorted cultures and strongly supported the polyclonal TCRgd expression on gd T cells activated to proliferate by aAPCs and cytokines.
IFNg produced in response to tumors is dependent on TCRgd
A multiplex analysis of cytokines and chemokines was performed to determine whether aAPC-propagated gd T cells might foster a proinflammatory response in a tumor microenvironment (Fig. 4A) . The Th1-associated cytokines IFNg and TNFa were secreted in abundance by gd T cells upon exposure to leukocyte-activated cocktail (LAC; PMA and ionomycin for nonspecific mitogenic stimulation), in addition to small amounts of IL2 and IL12 p70. In contrast, no significant production of the Th2-associated cytokines IL4, IL5, and IL13 was observed from LAC-treated gd T cells, but there was a small increase in IL10 production over baseline. Similarly, Th17-associated cytokines IL1RA, IL6, and IL17 were secreted at low levels by LAC-treated gd T cells. The chemokines CCL3, CCL4, CCL5, and CXCL8 were detected in abundance. Minor contributions of non-gd T cells in the culture that could have been activated by LAC to secrete cytokines could not be ruled out, but given that the cells tested were 97.9% AE 0.6% CD3 TCRgd staining in Vd1, Vd2, and Vd1 neg Vd2 neg T-cell subsets where each shape represents a different donor and data are mean AE SD (n ¼ 4) pooled from two independent experiments. C, proliferation of each isolated Vd subset stimulated twice with aAPC clone #4 (arrows) in presence of cytokines and total cell counts are displayed. Data are mean AE SD (n ¼ 4) pooled from 2 independent experiments. D, DTEA was used to identify and measure abundance of mRNA species coding for TRDV1, TRDV2-2, and TRDV3 (from left to right) in gd T-cell subpopulations after 15 days of proliferation on aAPCs and cytokines as separated subsets. Box and whiskers plots display 25% and 75% percentiles where lines represent maximum, mean, and minimum from top to bottom (n ¼ 4). Student paired, two-tailed t tests were undertaken for statistical analyses between groups. ÃÃ , P < 0.01; ÃÃÃ , P < 0.001.
of all the assessed cytokines and was chosen to measure responses of Vd subsets to tumor cells (Fig. 4B) . Coculture of polyclonal aAPC-propagated/activated gd T cells with cancer cells resulted in a hierarchy of IFNg production following Vd2>Vd1>Vd1 neg Vd2 neg as shown by MFI of 855 AE 475, 242 AE 178, and 194 AE 182 (mean AE SD; n ¼ 4), respectively. IFNg production by Vd1, Vd2, and Vd1 neg Vd2 neg subsets was inhibited by pan-TCRgd antibody when added to gd T-cell/tumor cocultures indicating that response to the tumor in each subset was dependent upon activation through TCRgd (Fig. 4C) . This observation supported the premise that a single cancer cell could be targeted by discrete gd TCRs. Thus, a multivalent proinflammatory response to the tumor cell was achieved by polyclonal gd T cells.
Polyclonal gd T cells lyse a broad range of tumor cells through combination of DNAM1, NKG2D, and TCRgd
After establishing that propagated gd T cells could be activated to produce proinflammatory cytokines, we examined their ability to specifically lyse a panel of tumor cell lines. Polyclonal gd T cells demonstrated a range of cytolysis against solid and hematologic cancer cell lines without a clear preference towards a particular tumor histology or grade ( Fig. 5 and Supplementary Fig. S11 ). We previously established that B-cell acute lymphoblastic leukemia (ALL) cell line NALM-6 was largely resistant to lysis by gd T cells, which required a CD19-specific CAR to acquire significant killing capability (27) . In this study, it was also observed that autologous and allogeneic normal B cells were spared from cytolysis (Fig. 5A) , and that B-ALL cell line cALL-2 and murine T-cell lymphoma cell line EL4 were lysed poorly by polyclonal gd T cells, which indicated that some cells were resistant and/or not recognized by polyclonal gd T cells. In contrast, T-ALL cell line Jurkat and B-ALL cell lines RCH-ACV were both killed efficiently by polyclonal gd T cells (Fig. 5B) , indicating that gd T cells could be used to target some B-cell and T-cell malignancies. Kasumi-3 is a CD33 þ
CD34
þ undifferentiated leukemia cell line that was lysed at intermediate levels by gd T cells. Chronic myelogenous leukemia (CML) cell line K562 and K562-derived clone#4 aAPCs were killed by polyclonal gd T cells, which corroborated the notion that these cells could serve as a proliferative substrate. Pancreatic cancer cell lines BxPc-3, MiaPaCa-2, and Su8686, were lysed by gd T cells, as was the colon carcinoma cell line HCT-116 (Fig. 5C ). Ovarian cell lines were killed by polyclonal gd T cells in the following order of decreasing sensitivity:
Each of the separated Vd subsets lysed hematologic (Jurkat and K562) and solid (OC314 and CAOV3) tumor cell lines, which showed that polyclonal gd T cells could direct a multivalent response against common targets (Supplementary Fig. S12 ). The strength of cytolysis followed the Tissue culture supernatants were interrogated using 27-Plex Luminex array to detect presence of (A) Th1, Th2, and Th17 cytokines and selected chemokines (from left to right). Data are mean AE SD pooled from 4 donors in two independent experiments where each donor had triplicate experimental wells pooled before multiplex analysis. Student one-tailed t test performed for statistical analysis between mock and LAC groups. Ã , P < 0.05; ÃÃ , P < 0.01; and ÃÃÃ , P < 0.001. B, polyclonal gd T cells were incubated for 1 hour before and during 6-hour tumor cell coculture with normal mouse serum or neutralizing TCRgd antibody (clone IM). Cells were stained for TCRd1, TCRd2, CD3, and IFNg to gate T-cell subsets and assess IFNg production. Comparisons of histograms detailing Vd1, Vd2, and Vd1 hierarchy of TCR usage (Vd2>Vd1 neg Vd2 neg >Vd1) that was consistent with the premise that a propensity to be triggered for effector function would increase with T-cell differentiation (Supplementary Fig. S13 ). Lysis by polyclonal populations was apparently not due to one specific Vd subtype but rather from contributions of multiple gd T-cell subsets, because it was observed that (i) a number of tumor cell lines were equivalently killed by polyclonal gd T cells containing different frequencies of Vd1, Vd2, and Vd1 neg Vd2 neg cells and (ii) a polyclonal population was not identified with dominant cytolysis. We also sought to determine which surface molecules were responsible for cytolysis by blocking immunoreceptors with antibodies (Fig. 5D) . Our experimental approach also took into account that gd T cells coexpress DNAM1 (97.7% AE 0.9%; mean AE SD; n ¼ 4) and NKG2D (40.1% AE 16.5%) which can activate both T cells and NK cells for killing (32, 33) . Addition of individual antibodies did not reduce lysis, except for TCRgd in 2 of 3 cell lines tested. In contrast, a pool of antibodies binding NKG2D, DNAM1, TCRgd resulted in significant inhibition, in a dose-dependent manner, of gd T-cell-mediated cytolysis against all 3 targets. Collectively, these data established that ex vivopropagated gd T cells have broad antitumor capabilities likely mediated by activation though DNAM1, NKG2D, and TCRgd. HCT-116, and ovarian cancer: OC314 and CAOV3. Data are mean AE SD (n ¼ 3 wells/assay) from two independent experiments. D, neutralizing antibodies to NKG2D (squares), DNAM1 (triangles), TCRgd (inverted triangles), or a pool (diamonds) of all three antibodies were used to block killing of Jurkat (left), IGROV1 (middle), or OC314 (right) tumor targets antibodies at 0.3, 1, and 3 mg/mL and an E:T ratio of 12:1 in standard 4-hour CRA. Normal mouse serum (circles) served as control for addition of antibody and wells without antibody were used for normalization purposes. Specific lysis was normalized to wells without antibody to yield relative cytolysis as defined by: Relative cytolysis (%) ¼ (Specific Lysis)With Antibody/(Specific Lysis)Without Antibody Â 100. Data are mean AE SD (n ¼ 4 donors) from triplicates pooled and normalized from two independent experiments. Repeated-measures two-way ANOVA was used for statistical analysis between antibody treatments. ÃÃ , P < 0.01; ÃÃÃ , P < 0.001.
Established ovarian cancer xenografts are eliminated by adoptive transfer of gd T cells
To test whether polyclonal gd T cells were effective in targeting and killing tumors in vivo, we created a xenograft model for ovarian cancer in immunocompromised mice. NSG mice were injected intraperitoneally with CAOV3-effLuc-mKate ovarian cancer cells and then randomized into five treatment groups. After 8 days of tumor engraftment, either PBS (vehicle/mock), Vd1, Vd2, Vd1 neg Vd2 neg , or polyclonal gd T cells were administered in escalating doses (Fig. 6) . Tumor burden and biodistribution were serially measured by noninvasive BLI. Established tumors continued to grow in vehicle-treated mice, but tumor bioburden was significantly reduced (P 0.001) in mice receiving gd T-cell treatments at day 72, relative to their initial tumor burden (Fig. 6A and B) . Adoptive transfer of polyclonal gd T cells, Vd1, and Vd1 neg Vd2 neg T cells significantly (P 0.01), and Vd2 almost significantly (P ¼ 0.055), increased long-term survival compared with mock-treated mice. This corresponded to overall survival following polyclonal>Vd1>Vd1 neg Vd2 neg >Vd2 (Fig. 6C) . This is the first time that three Vd subsets have been compared for their ability to target tumor in vivo and is the first display of in vivo antitumor activity by Vd1 neg Vd2 neg cells. In sum, activated and propagated gd T cells were effective in treating cancer in vivo and thus represent an attractive approach to adoptive immunotherapy.
Discussion
This study establishes our aAPC clone #4 as a cellular platform for the sustained proliferation of multiple gd T-cell populations that demonstrate extensive reactivity against hematologic and solid malignancies. T cells expressing defined Vd TCRs have been associated with clinical responses against cancer. For example, the Vd1 subset correlated with complete responses observed in patients with ALL and acute myelogenous leukemia (AML) after ab , and polyclonal gd T-cell treatment groups. Images are representative of 6 to 14 mice from two independent experiments. B, BLI measurements of mice at day 0 (white) and day 72 (gray) pooled from two independent experiments. Box and whiskers plots display 25% and 75% percentiles where lines represent maximum, mean, and minimum from top to bottom (n ¼ 6-14). Student paired, two-tailed t tests were used for statistical analysis between time points. C, overall survival of mice treated with PBS (dashed), polyclonal (black), Vd1 (red), Vd2 (blue), or Vd1 neg Vd2 neg (green) gd T cells.
Log-rank (Mantel-Cox) test was used to calculate P values. Ã , P < 0.05; ÃÃ , P < 0.01; and ÃÃÃ , P 0.001.
T-cell-depleted haploidentical HSCT (15) (16) (17) . Vd1 cells were also shown to kill glioblastoma independent of cytomegalovirus (CMV) status (34 The molecules on aAPCs that activate gd T cells for numeric expansion are not well known. K562-derived aAPCs express endogenous MHC class-I chain-related protein A and B (MICA/B) which are ligands for both Vd1 and NKG2D (6, 40) . Indeed, NKG2D was observed on polyclonal gd T cells that also predominantly expressed Vd1 TCR (Fig. 1A) . Polyclonal gd T cells also demonstrate expression for activating receptors typically found on NK cells (NKp30, NKp44, and NKp46; collectively expressed at 26% AE 7%), and future studies will examine their contribution to gd Tcell effector function. Some malignant cells were recognized poorly by gd T cells, for e.g., EL4, EFO27, OAW42, cALL-2, and NALM-6, which provides an opportunity to further interrogate the mechanism by which gd T cells recognize and kill tumor cells. Given that inhibition of cytolysis was maximized by neutralizing DNAM1, NKG2D, and TCRgd receptors simultaneously, it may be that sensitivity of a tumor cell resides on the expression of ligand combinations that can bind these receptors. Two ligands recognized by Vd2 TCR are surface mitochondrial F 1 -ATPase and phospho-antigens, both of which are found in K562 cells (41, 42) . Enhanced responses of T cells expressing Vg9Vd2 were observed when K562 cells were treated with aminobisphosphonates (41) and a similar strategy could be employed upon coculture with aAPC clone #4 to increase the abundance of T cells bearing Vd2 TCR (18) . Future studies will evaluate additional TCRgd ligands that naturally occur in these aAPCs.
We enforced expression of costimulatory molecules to ascertain and improve the capability of K562-derived aAPCs to propagate gd T cells expressing a diversity of TCR. Indeed, CD137L was the dominant costimulatory proliferative signal on aAPCs for expansion of gd T cells with broad tumor reactivity (Fig. 1C) , and its receptor, CD137, has been used to enrich tumor-reactive ab T cells following antigen exposure and presumably TCR stimulation (43) (44) (45) . CD137 was not expressed on resting gd T cells before expansion, suggesting that the importance of CD137L costimulation by aAPCs followed TCR stimulation by the aAPCs and expression of CD137 on the gd T-cell surface. CD27
þ and CD27 neg gd T cells have been shown to produce IFNg and IL17 (46), respectively; therefore, CD27 could be used as a marker for isolating gd T cells with a preferred cytokine output. ICOSligand in absence of CD86 was shown to polarize CD4 þ ab T cells to produce IL17 instead of IFNg (47), and current studies are investigating whether combinations of costimulatory molecules can selectively propagate cytokine-producing subpopulations of gd T cells. Thus, the aAPC coculture system in the context of desired cytokines provides a clinically relevant methodology to tailor the type of therapeutic gd T cell produced for adoptive immunotherapy. Our data have implications for the design and interpretation of clinical trials. Expression of IL15 was important for the maintenance of transferred gd T cells in vivo (48) , supporting the use of IL15 on aAPCs, and future studies could inform on other molecules that could be introduced to maximize the cell therapy product. Correlative studies are enhanced by our observation that TCRgd mAb can be used to readily distinguish the three (Vd1, Vd2, and Vd1 neg Vd2 neg ) T-cell subsets based on MFI of TCRgd expression (Fig. 3B) . Given that gd T cells are not thought to recognize ligands in the context of MHC (17), there is potential to infuse allogeneic, including third party, gd T cells in lymphodepleted hosts to achieve an antitumor effect while mitigating the risk of graft versus host disease. Restoration of lymphopoiesis may result in graft rejection, but a therapeutic window could be established whereby tumors are directly killed by infused gd T cells, which may result in desired bystander effects as conserved or neoantigens are presented to other lymphocytes. Indeed, gd T cells have been shown to lyse cancer cells, cross-present tumor-specific antigens to ab T cells, and license them to kill tumors (49, 50) . The aAPC clone #4 has been produced as a master cell bank in compliance with current good manufacturing practice and provides a clear path to generating clinical-grade gd T cells for human application. Human trials can now, for the first time, test the efficacy of adoptive transfer of T cells with polyclonal TCRgd repertoire for treatment of solid and hematologic tumors.
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